L-carnitine alleviates alcohol-induced liver damage in rats: role of tumour necrosis factor-alpha.
about
Nutritional and anti-inflammatory interventions in chronic heart failure.Failure of carnitine in improving hepatic nitrogen content in alcoholic and non-alcoholic malnourished rats.Alterations in Hepatic FGF21, Co-Regulated Genes, and Upstream Metabolic Genes in Response to Nutrition, Ketosis and Inflammation in Peripartal Holstein Cows.Early-phase alcoholic liver disease: an update on animal models, pathology, and pathogenesis.Mitochondrial glutathione and chemically induced stress including ethanol.A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.Effects of Puerariae Radix Extract on Endotoxin Receptors and TNF-α Expression Induced by Gut-Derived Endotoxin in Chronic Alcoholic Liver Injury.Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.Metabolic syndrome in drug abuse.l-carnitine protects human hepatocytes from oxidative stress-induced toxicity through Akt-mediated activation of Nrf2 signaling pathway.Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha.The influence of L-carnitine suplementation on the antioxidative abilities of serum and the central nervous system of ethanol-induced rats.Neuroprotective strategies in drug abuse-evoked encephalopathy.Pharmacological evaluation of a β-hydroxyphosphonate analogue of l-carnitine in obese Zucker fa/fa rats.L-Carnitine induces recovery of liver lipid metabolism in cancer cachexia.Hepatocyte proliferation is the possible mechanism for the transient decrease in liver injury during steatosis stage of alcoholic liver disease.Effect of chronic ethanol administration on hepatic eNOS activity and its association with caveolin-1 and calmodulin in female rats.Carnitine deficiency: a possible risk factor in paracetamol hepatotoxicity.L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death.Effect of Genistein and L-carnitine and Their Combination on Lipid Profile and Inflammatory Cytokines in Experimental Nephrotic Syndrome
P2860
Q33880185-792D9168-0081-4AA5-BA25-37F17AB257A9Q34197968-543FAA49-D3CC-46CF-B419-9068EA82585CQ35801597-0DBCE04F-B9FB-48CB-9B9A-F60268C62468Q35889127-4F6E61DC-0E5C-4229-9AEC-F473864F78A8Q35956163-62EC04AE-5492-4A4B-A014-9E0C034DB18EQ36172470-025E0B22-6184-4739-AA18-7B9C95DCE8CCQ36361094-C8CDAE19-730E-448B-AD9A-30BACC663B3CQ36983539-0DCC2708-73FD-4DE7-96ED-8F158186ED2CQ37031208-D9EC172B-F31D-49BD-8FCB-EC275C359A41Q38793210-E3B08878-C0E6-40EE-B35A-9B6C61D4DAEDQ39376036-99041A35-1E99-4C45-AA33-FBCFD0334729Q42822222-EBDFBE4C-B252-46E0-9ACB-6B08A5059353Q42969550-790F440C-6F8C-42BB-9B12-30E87B477749Q43478611-D6B32880-B6B6-4AC0-B0DA-AAB5D204294EQ43493969-ED6E1C25-87E9-4FEF-A275-2F244B5C12D3Q45189735-1D7873F1-CE56-4CF4-87AC-1290D816C666Q46450232-C816527D-3314-4484-AA1D-8E24FB3AA9CAQ46505391-62B6DBD7-1FAD-4CC8-9931-72BD78B74190Q46931605-D38AB531-7FB9-44AF-A0C6-624F8BB879E8Q57489070-12857D07-D66B-4582-9624-856B068096FA
P2860
L-carnitine alleviates alcohol-induced liver damage in rats: role of tumour necrosis factor-alpha.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@en
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@nl
type
label
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@en
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@nl
prefLabel
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@en
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@nl
P2093
P356
P1476
L-carnitine alleviates alcohol ...... tumour necrosis factor-alpha.
@en
P2093
P304
P356
10.1093/ALCALC/AGG109
P577
2003-09-01T00:00:00Z